What Palvella Therapeutics, Inc. told the SEC could break it.

Palvella's lead active pharmaceutical ingredient, rapamycin, is currently sourced from suppliers located in India; any disruption or quality problem could delay its development programs and ability to manufacture its product candidates.

“Our active pharmaceutical ingredient, rapamycin, is currently sourced from suppliers located in India.”

Pre-revenue clinical-stage Palvella had a $135.5M accumulated deficit at year-end 2025, expects continued significant losses for several years, has never generated product revenue, and will likely need additional dilutive funding.

“As of December 31, 2025, we had an accumulated deficit of $135.5 million. We expect to continue to incur significant operating losses for at least the next several years, and we may never achieve or sustain profitability.”

If approved, Palvella's products would face US drug-pricing pressure — IRA-mandated Medicare price negotiation plus proposed MFN models (GLOBE for Part B, GUARD for Part D) tying single-source drug rebates to international benchmark prices.

“The IRA also requires HHS to negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D. The negotiated price may not exceed a statutory ceiling price.”

Palvella relies on CMOs for QTORIN rapamycin drug-product manufacture and packaging and only plans to add backup suppliers as it advances development — implying current single-source exposure for drug product.

“as we advance QTORIN rapamycin through development, we will add backup suppliers for drug product manufacture and packaging to protect against any potential supply disruptions.”